AcadeMab develops therapy for COVID-19 Omicron variant with potent neutralizing efficacy

30 May 2022

coronavirus_credit_deposit_photos-_largre

Taiwanese biotech firm AcadeMab has broken new ground in the development of immunotherapies through the development of a potentially life-saving monoclonal antibodies (MAbs) for COVID-19 patients using single B cell technology, shows the best neutralization ability (IC50 = 11.4 and 4.3 ng/ml) in both Omicron variants BA.1 and BA.2 respectively.

AcadeMab's treatment specifically targets the SARS-CoV-2 Omicron variant - currently the most common strain of COVID infections around the world.

"In a world ravaged by the COVID-19 pandemic with rapidly mutating variants emerging ever so often, it is a race for the scientific community to develop new therapies in a timely manner. We are excited to announce that our research and development efforts have paid off at a fast pace with our single B cell technology that's shown neutralizing efficacy against the world's most common and deadly Omicron variant," said Dr Juz-Hsiang Chiu, AcadeMab chief executive.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK